NO304010B1 - FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer - Google Patents
FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer Download PDFInfo
- Publication number
- NO304010B1 NO304010B1 NO922004A NO922004A NO304010B1 NO 304010 B1 NO304010 B1 NO 304010B1 NO 922004 A NO922004 A NO 922004A NO 922004 A NO922004 A NO 922004A NO 304010 B1 NO304010 B1 NO 304010B1
- Authority
- NO
- Norway
- Prior art keywords
- budesonide
- water
- epimer
- polymer
- insoluble
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims description 38
- 239000008188 pellet Substances 0.000 title claims description 33
- 238000009472 formulation Methods 0.000 title claims description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 78
- 229960004436 budesonide Drugs 0.000 claims abstract description 78
- 210000000813 small intestine Anatomy 0.000 claims abstract description 10
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 24
- 230000000968 intestinal effect Effects 0.000 claims description 21
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 210000004051 gastric juice Anatomy 0.000 claims description 12
- 125000000129 anionic group Chemical group 0.000 claims description 10
- 229920003169 water-soluble polymer Polymers 0.000 claims description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- 230000000181 anti-adherent effect Effects 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 19
- 208000011231 Crohn disease Diseases 0.000 abstract description 17
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 208000014997 Crohn colitis Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 13
- 239000006185 dispersion Substances 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 8
- 238000007922 dissolution test Methods 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000009115 maintenance therapy Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 231100000987 absorbed dose Toxicity 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 241000792859 Enema Species 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
- 229920003141 Eudragit® S 100 Polymers 0.000 description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
- 206010036774 Proctitis Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical group C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- -1 anti-adhesives Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940094157 budesonide enema Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000014964 small bowel Crohn disease Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8903914A SE8903914D0 (sv) | 1989-11-22 | 1989-11-22 | Oral composition for the treatment of inflammatory bowel diseases |
| PCT/SE1990/000738 WO1991007172A1 (en) | 1989-11-22 | 1990-11-15 | Oral composition for the treatment of inflammatory bowel diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922004D0 NO922004D0 (no) | 1992-05-21 |
| NO922004L NO922004L (no) | 1992-05-21 |
| NO304010B1 true NO304010B1 (no) | 1998-10-12 |
Family
ID=20377544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922004A NO304010B1 (no) | 1989-11-22 | 1992-05-21 | FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6423340B1 (xx) |
| EP (1) | EP0502092B1 (xx) |
| JP (1) | JP3145111B2 (xx) |
| KR (1) | KR0179042B1 (xx) |
| AT (1) | ATE125445T1 (xx) |
| AU (1) | AU643021B2 (xx) |
| CA (1) | CA2071518C (xx) |
| DE (1) | DE69021214T2 (xx) |
| DK (1) | DK0502092T3 (xx) |
| EG (1) | EG19642A (xx) |
| ES (1) | ES2074698T3 (xx) |
| FI (2) | FI104949B (xx) |
| GR (1) | GR3017691T3 (xx) |
| HK (1) | HK51897A (xx) |
| HR (1) | HRP920632B1 (xx) |
| HU (2) | HU216836B (xx) |
| IE (1) | IE74854B1 (xx) |
| IL (1) | IL96415A (xx) |
| IS (1) | IS1858B (xx) |
| LT (1) | LT3696B (xx) |
| LV (1) | LV10183B (xx) |
| MY (1) | MY104535A (xx) |
| NO (1) | NO304010B1 (xx) |
| NZ (1) | NZ235807A (xx) |
| PL (1) | PL166506B1 (xx) |
| PT (1) | PT95946A (xx) |
| RU (1) | RU2134104C1 (xx) |
| SA (1) | SA90110123B1 (xx) |
| SE (1) | SE8903914D0 (xx) |
| SG (1) | SG54210A1 (xx) |
| SI (1) | SI9012150A (xx) |
| TW (1) | TW250435B (xx) |
| UA (1) | UA37196C2 (xx) |
| WO (1) | WO1991007172A1 (xx) |
| YU (1) | YU48583B (xx) |
| ZA (1) | ZA908777B (xx) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| JP3366640B2 (ja) * | 1993-01-08 | 2003-01-14 | アストラ・アクチエボラーグ | 新規な結腸−または回腸−特異的ステロイド誘導体 |
| US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4332394A1 (de) * | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
| US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| AU739031B2 (en) * | 1996-11-15 | 2001-10-04 | Procter & Gamble Company, The | Pharmaceutical dosage form for colonic delivery |
| SE9604751D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Ab | New therapy |
| DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| US6239120B1 (en) | 1998-03-17 | 2001-05-29 | Pharmalink Ab | Method and means for treating glomerulonephritis |
| GB9824604D0 (en) | 1998-11-11 | 1999-01-06 | Hewlett Healthcare Limited | Treatment of allergic conditions |
| SE9902673D0 (sv) * | 1999-07-12 | 1999-07-12 | Astra Ab | New composition |
| DE60237363D1 (de) * | 2001-03-15 | 2010-09-30 | Soligenix Inc | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden |
| DE10250543A1 (de) * | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| ES2312844T3 (es) | 2002-12-12 | 2009-03-01 | Nycomed Gmbh | Medicamento de combinacion de r, r-formoterol y ciclesonida. |
| US20060188563A1 (en) * | 2003-03-27 | 2006-08-24 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis |
| US20060211668A1 (en) * | 2003-09-15 | 2006-09-21 | Altana Pharma Ag | Use of ciclesonide for the treatment of inflammatory bowel diseases |
| ES2452691T5 (es) | 2003-09-16 | 2022-09-14 | Covis Pharma Gmbh | Uso de ciclesonida para el tratamiento de enfermedades respiratorias |
| AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
| US20070243184A1 (en) * | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| WO2008117814A1 (ja) * | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
| GB0808537D0 (en) | 2008-05-12 | 2008-06-18 | Archimedes Dev Ltd | Compositions |
| EP2334178A4 (en) * | 2008-10-03 | 2012-04-11 | Falk Pharma Gmbh | COMPOSITIONS AND METHODS OF TREATING THERAPEUTIC DISEASES WITH GRANULATED MESALAMINE |
| US8945615B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
| US8945616B2 (en) | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
| WO2012106722A2 (en) * | 2011-02-04 | 2012-08-09 | Optimer Pharmaceuticals, Inc. | Treatment of bacterial infections |
| MD480Z (en) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Method for treating acute ulcerative nonspecific colitis |
| LT2659881T (lt) | 2012-04-30 | 2018-02-12 | Tillotts Pharma Ag | Uždelsto atpalaidavimo vaisto forma |
| EP3542791A1 (en) | 2013-10-29 | 2019-09-25 | Tillotts Pharma AG | A delayed release drug formulation |
| EP3346996A4 (en) * | 2015-09-11 | 2019-04-17 | Sun Pharmaceutical Industries Limited | ORAL PHARMACEUTICAL PHARMACEUTICAL FORM OF BUDESONID |
| CN105663091A (zh) * | 2016-01-28 | 2016-06-15 | 上海信谊百路达药业有限公司 | 一种布地奈德肠溶缓释胶囊及其制备方法 |
| RU2750944C2 (ru) * | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| EP3413878B1 (en) * | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
| EP3613414A1 (de) | 2018-08-24 | 2020-02-26 | Dr. Falk Pharma Gmbh | Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996356A (en) | 1969-07-02 | 1976-12-07 | Hoffmann-La Roche Inc. | Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine |
| SE378109B (xx) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE7813246L (sv) | 1978-12-22 | 1980-06-23 | Haessle Ab | Fast farmaceutisk beredning innehallande kroppar med flera ytskikt |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
| SE8008524L (sv) | 1980-12-04 | 1982-06-05 | Draco Ab | 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| SE8306370D0 (sv) | 1983-11-18 | 1983-11-18 | Draco Ab | Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions |
| US4708867A (en) | 1983-12-19 | 1987-11-24 | Key Pharmaceuticals, Inc. | Minipellets |
| US4606940A (en) | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
| DE3536267A1 (de) | 1985-10-11 | 1987-04-16 | Bayer Ag | Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe |
| SE8506015D0 (sv) | 1985-12-19 | 1985-12-19 | Draco Ab | Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives |
| GB8630913D0 (en) | 1986-12-24 | 1987-02-04 | Glaxo Group Ltd | Pharmaceutical compositions |
| US4966770A (en) | 1989-07-26 | 1990-10-30 | Himedics, Inc. | Prednisone microencapsulated granules |
| DE10307386A1 (de) | 2003-02-21 | 2004-09-09 | Dieter Wildfang Gmbh | Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil |
-
1989
- 1989-11-22 SE SE8903914A patent/SE8903914D0/xx unknown
-
1990
- 1990-10-24 NZ NZ235807A patent/NZ235807A/xx unknown
- 1990-11-01 ZA ZA908777A patent/ZA908777B/xx unknown
- 1990-11-07 SA SA90110123A patent/SA90110123B1/ar unknown
- 1990-11-07 TW TW079109396A patent/TW250435B/zh active
- 1990-11-13 YU YU215090A patent/YU48583B/sh unknown
- 1990-11-13 SI SI9012150A patent/SI9012150A/sl unknown
- 1990-11-15 UA UA94051483A patent/UA37196C2/uk unknown
- 1990-11-15 SG SG1996004385A patent/SG54210A1/en unknown
- 1990-11-15 EP EP91900414A patent/EP0502092B1/en not_active Revoked
- 1990-11-15 HU HU9201700A patent/HU216836B/hu unknown
- 1990-11-15 US US09/159,301 patent/US6423340B1/en not_active Expired - Fee Related
- 1990-11-15 DE DE69021214T patent/DE69021214T2/de not_active Revoked
- 1990-11-15 AU AU77864/91A patent/AU643021B2/en not_active Expired
- 1990-11-15 KR KR1019920701202A patent/KR0179042B1/ko not_active IP Right Cessation
- 1990-11-15 HU HU9201700A patent/HUT60630A/hu unknown
- 1990-11-15 ES ES91900414T patent/ES2074698T3/es not_active Expired - Lifetime
- 1990-11-15 DK DK91900414.3T patent/DK0502092T3/da active
- 1990-11-15 RU SU5052239A patent/RU2134104C1/ru active
- 1990-11-15 CA CA002071518A patent/CA2071518C/en not_active Expired - Lifetime
- 1990-11-15 JP JP50070991A patent/JP3145111B2/ja not_active Expired - Lifetime
- 1990-11-15 WO PCT/SE1990/000738 patent/WO1991007172A1/en not_active Application Discontinuation
- 1990-11-15 AT AT91900414T patent/ATE125445T1/de not_active IP Right Cessation
- 1990-11-20 IE IE417090A patent/IE74854B1/en not_active IP Right Cessation
- 1990-11-20 IL IL9641590A patent/IL96415A/en active IP Right Review Request
- 1990-11-20 EG EG69190A patent/EG19642A/xx active
- 1990-11-20 PL PL90287844A patent/PL166506B1/pl unknown
- 1990-11-21 PT PT95946A patent/PT95946A/pt not_active Application Discontinuation
- 1990-11-21 IS IS3644A patent/IS1858B/is unknown
- 1990-11-21 MY MYPI90002053A patent/MY104535A/en unknown
-
1992
- 1992-05-21 NO NO922004A patent/NO304010B1/no not_active IP Right Cessation
- 1992-05-21 FI FI922325A patent/FI104949B/fi active
- 1992-09-30 HR HRP-2150/90A patent/HRP920632B1/xx not_active IP Right Cessation
-
1993
- 1993-08-10 LV LVP-93-1026A patent/LV10183B/en unknown
- 1993-12-31 LT LTIP1751A patent/LT3696B/lt not_active IP Right Cessation
-
1995
- 1995-10-11 GR GR950402797T patent/GR3017691T3/el unknown
-
1997
- 1997-04-24 HK HK51897A patent/HK51897A/xx not_active IP Right Cessation
-
1999
- 1999-09-06 FI FI991893A patent/FI19991893A/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO304010B1 (no) | FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer | |
| US5643602A (en) | Oral composition for the treatment of inflammatory bowel disease | |
| JP3194974B2 (ja) | 標的制御釈放薬剤 | |
| JP4088413B2 (ja) | 腸管を処置・治療するペレット製剤 | |
| CA2683407C (en) | Pharmaceutical cyclosporin compositions | |
| CA1302262C (en) | Pharmaceutical composition containing flutiasone propionate | |
| EP0040590A2 (en) | A pharmaceutical preparation having improved release properties | |
| CZ281792B6 (cs) | Orálně podávatelná farmaceutická dávkovací forma pro selektivní podávání léčiva do střev | |
| ITMI20001603A1 (it) | Formulazioni farmaceutiche solide orali a rilascio multifasico ph-dipendente | |
| JPH09504280A (ja) | センナ剤形 | |
| EP1315481A1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| JP3469926B2 (ja) | 大腸内放出型医薬製剤用粒状物 | |
| EP0956006A1 (en) | Colonic delivery of weak acid drugs | |
| EP1100481B1 (en) | Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease | |
| CA2538202C (en) | Use of ciclesonide for the treatment of inflammatory bowel diseases | |
| WO1994007503A1 (en) | Enteric preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |